News

XARTEMIS XR’s release profile combines Mallinckrodt’s newly patented technology, including design, formulation, pharmacokinetic and release characteristics, and Depomed’s advanced Acuform drug delivery technology. The drug is the first

Qudexy XR is indicated as initial monotherapy in patients ten years of age and older with POS or primary generalized tonic-clonic seizures. The once-daily, broad-spectrum antiepileptic drug is

The solution is indicated for the production of topical anesthesia of accessible mucous membranes of the oral and nasal cavities and proximal portions of the digestive tract. IGI

This is the first application of Intravail in a solid dosage form. The Intravail formulation is compatible with current tableting processes employed for OTC and prescription drugs and

Burman’s knew that when these drugs hit the market, they were going to require intensive management in order to reach their potential for eliminating HCV in most patients.

ChromaDex will provide GBB with quantities of its proprietary NIAGEN nicotinamide riboside (NR) ingredient. NIAGEN is the first and only commercially available form of NR, a naturally-occurring vitamin

With this contract award ClinicalRM becomes part of a clinical studies network being established by BARDA to support development of vaccines, drugs, and diagnostics, known as medical countermeasures,

Under the agreement, Zubsolv will be given preferred, Tier 2 brand status on UHG commercial employer and individual formularies managed by OptumRx for the maintenance treatment of opioid

The trial, which evaluated the efficacy of two dose regimens of mepolizumab, also met its primary endpoint of reduction in the frequency of exacerbations. Throughout the trial, patients